Yale Cancer Center and Smilow Cancer Hospital Physicians and Scientists Presenting Latest Advances at 2023 ASCO Annual Meeting
Yale Cancer Center and Smilow Cancer Hospital scientists and clinicians will present new research at the 2023 Annual Meeting of the American Society of Clinical Oncology, June 2nd to June 6th at McCormick Place in Chicago, Illinois.
Study Finds Large Gap in Breast Cancer Treatment Recommendations for Patients Aged 70 vs 69
Age-based heuristics can lead to large differences in breast cancer treatment based on small differences in chronologic age, according to a new analysis of more than 500,000 patient records.
Barbara Burtness Named Chief Translational Research Officer for Yale Cancer Center and Smilow Cancer Hospital
Barbara Burtness, MD, has been named Chief Translational Research Officer for Yale Cancer Center and Smilow Cancer Hospital and Associate Cancer Center Director for Translational Research for Yale Cancer Center.
Oncology Therapy at the End of Life: Have We Missed the Mark?
Continued treatment for patients with cancer near end of life delays conversations about goals of care and hospice enrollment, escalates costs, and may adversely affect the quality of care patients receive.
Yale Research Reveals “Biologically Older” Tissue in Patients with Breast Cancer
An analysis by Yale Cancer Center researchers identified accelerated genetic aging in breast tissue adjacent to breast cancer tumors.
Yale Scientists Develop Precision Medicine Approach to Metabolic Therapy for Breast Cancer
Scientists at Yale Cancer Center have found that patients with breast cancer and high levels of insulin in the blood may be responsive to metabolism-targeting treatments, which in turn may improve the effectiveness of subsequent chemotherapy treatments.
Combination Immunotherapy Improves Outcomes for Patients with Non-small Cell Lung Cancer
The phase 2 clinical trial of a multi-center study known as the COAST clinical trial has demonstrated improved outcomes using immunotherapy combinations for patients with unresectable stage III non–small cell lung cancer.
Yale Findings Broaden the Repertoire of Cancer-Relevant Genes
Following an analysis of over 12,000 human genes, research from Yale Cancer Center indicates there is cancer-relevant importance in a much larger proportion of human genes than current cancer research models suggest.
Yale Scientists Discover a New Pathogenic Mechanism in Hematological Malignancies
Scientists at Yale Cancer Center have discovered new consequences of specific gene mutations that play a role in the development of myelodysplastic syndromes and acute myeloid leukemia.
‘Decision Switch’ Discovered in Mutations Linked to Common Brain Tumor
Researchers at the Yale Cancer Biology Institute have clarified the role of a recurring cancer-associated tumor mutation in glioblastoma multiforme, the most common and most aggressive type of malignant brain tumor.
Yale Cancer Center and School of Public Health Receive Grant to Study Lifestyle Intervention in Women with Ovarian Cancer
The National Cancer Institute recently awarded Yale Cancer Center and Yale School of Public Health a new U01 cooperative agreement grant to support research into the impact of diet and exercise for women with ovarian cancer.
New Class of Oncogenic Fusions Revealed in Lung and Pancreatic Cancer
A Yale Cancer Center research team has identified novel oncogenic gene fusions in lung and pancreatic cancer, as well as sarcoma. The fusions involve RASGRF1 (an activator of RAS signaling) and promote cellular changes leading to tumor development.
Yale Cancer Center Scientists Create Next-Generation CRISPR Tool to Aid Gene Editing
New research led by Yale Cancer Center shows the creation of a next-generation CRISPR-Cas9 “off-switch” and precision tool to aid safe gene editing therapeutics in patients.
Yale Cancer Center Annual Conclave Awards Presented
Yale Cancer Center held its annual Conclave award ceremony virtually on February 15 to celebrate scientific and caregiver accomplishments in 2021
Yale Cancer Center Study Shows Many Older Patients with Chronic Myeloid Leukemia Not Appropriately Monitored or Adherent to Prescribed Therapy
New research led by Yale Cancer Center scientists shows less than a third of older patients with chronic myeloid leukemia had optimal laboratory monitoring and only two-thirds were adherent to TKI therapy during the first year after diagnosis.
Yale Cancer Center Study Reveals Disparities in Telemedicine Use in Patients with Hematologic Cancers
New research led by Yale Cancer Center revealed White patients had significantly more telemedicine visits compared with Black patients for hematologic cancer care during the COVID-19 pandemic.
Ian E. Krop, MD, PhD, Named Chief Clinical Research Officer, Associate Cancer Center Director for Clinical Research at Yale Cancer Center
Ian E. Krop, MD, PhD, has been appointed chief clinical research officer, associate cancer center director for clinical research, and director of the Yale Cancer Center Clinical Trials Office.
Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis
Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment
First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma
Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS
2 Clarke Drive Cranbury, NJ 08512